A Multicenter Study Assessing the Optimal Anticoagulation Strategies in COVID-19 Critically Ill Patients with New-Onset Atrial Fibrillation: Balancing Effectiveness and Safety.

Int J Gen Med · 2024 · PMC11612464 · PMID 39628980

Europe PMC DOI

hedged sentence

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

did not reach statistical significanceP = 0.14not close (p > 0.1)

37 Despite this numerical difference, it did not reach statistical significance (3.8% vs 1.3%, P = 0.14). 36 It is important to note that RAPID trial was conducted to compare treatment and prophylactic anticoagulation in critically ill patients with COVID-19 without focusing on Afib patients.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.